Novelos Therapeutics Announces Continued Encouraging Results In Ongoing Phase 2 Ovarian Cancer Trial At Dana-Farber/Harvard Cancer Center

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced continued encouraging results in an ongoing Massachusetts General Hospital Cancer Center and Dana-Farber/Harvard Cancer Center (DF/HCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients.

More: continued here

Filed under: Cancer on April 3rd, 2008